https://pubmed.ncbi.nlm.nih.gov/41409318/
Landmark trials of sotatercept in pulmonary arterial hypertension (PAH) excluded patients with significant cardiopulmonary comorbidities. To evaluate the...
real worldperformancesotaterceptpahpatients
https://www.ajmc.com/view/sotatercept-reduces-risk-of-death-transplant-or-hospitalization-in-advanced-pah?utm_source=www.ajmc.com&utm_medium=relatedContent
Patients taking sotatercept had a 76% relative risk reduction in morbidity and mortality events compared with patients taking placebo.
sotaterceptreducesriskdeathtransplant
https://www.benzinga.com/analyst-ratings/analyst-color/23/03/31243543/analyst-downgrades-gossamer-bio-as-mercks-sotatercept-might-overshadow-seralutinibs
analystdowngradesgossamerbiomerck